Why the study?
ARNI is under-prescribed in India despite its attractive safety and efficacy profile in heart failure.
This consensus statement from India highlights the under-prescription of ARNI and advocates for its early and effective dosing to promote cardiac reverse remodeling and improve heart failure outcomes.
Answers are grounded in this paper and cite their sources.
Start ARNI promptly in eligible Indian HFrEF patients; confirms remodeling benefits from RCTs and extends consensus to address underuse.
Adverse cardiac remodeling refers to progressive structural and functional modifications in the heart because of increased wall stress in the myocardium, loss of viable myocardium, and neurohormonal stimulation. The guideline-directed medical therapy for Heart failure (HF) includes Angiotensin receptor-neprilysin inhibitor (ARNI) (sacubitril/valsartan), β-blockers, sodium-glucose co-transporter 2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists (MRA). ARNI is under-prescribed in India despite its attractive safety and efficacy profile. Therefore, the consensus discusses objectives and topics related to ARNI in the management of cardiac remodeling, and experts shared their views on the early timely intervention of effective dosage of ARNI to improve the diagnosis and enhance mortality and morbidity benefits in cardiac reverse remodeling (CRR).
No takes yet. Share an insight, caveat, or question.
Chopra et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: